INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 15, 2004 |
VP, Regulatory Development
Trans History: 288
|
VP, Regulatory Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,188 | -- | 11,188 |
| Dec 15, 2004 |
VP, Regulatory Development
Trans History: 288
|
VP, Regulatory Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,812 | -- | 18,812 |
| Dec 15, 2004 |
SVP, Manuf & Process Sciences
Trans History: 109
|
SVP, Manuf & Process Sciences | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,537 | -- | 10,537 |
| Dec 15, 2004 |
SVP, Manuf & Process Sciences
Trans History: 109
|
SVP, Manuf & Process Sciences | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 64,463 | -- | 64,463 |
| Dec 15, 2004 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 398
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 31,611 | -- | 31,611 |
| Dec 15, 2004 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 398
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 218,389 | -- | 218,389 |
| Dec 15, 2004 |
SVP, PreclinDevel & Biomol Sci
Trans History: 626
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,537 | -- | 10,537 |
| Dec 15, 2004 |
SVP, PreclinDevel & Biomol Sci
Trans History: 626
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 89,463 | -- | 89,463 |
| Dec 15, 2004 |
Director
Trans History: 742
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 42,148 | -- | 42,148 |
| Dec 15, 2004 |
Director
Trans History: 742
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 270,352 | -- | 270,352 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.